SITE005-0104

withdrawn

Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE005 (FRA) (Dr. Muller) · consented 2022-06-29

Adverse events

Serious AEs

Open data queries

Luna dropout signal

–

Adverse events

severe serious assessed 2026-08-18

Grade 3 Pruritus — outcome: RECOVERED/RESOLVED; onset 2022-08-24 (study day 40); relationship: not assessed; serious criteria: hospitalization

moderate assessed 2026-08-18

Grade 2 Hyperthyroidism — outcome: RECOVERED/RESOLVED; onset 2022-09-21 (study day 68); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-07-20 (study day 370); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Decreased appetite — outcome: UNKNOWN; onset 2023-08-07 (study day 388); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-08-21 (study day 402); relationship: Y

severe serious assessed 2026-08-18

Grade 3 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-03-26 (study day 620); relationship: N; serious criteria: hospitalization

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.